Core Viewpoint - Guoen Technology (02768.HK) plans to globally offer 30 million H-shares, with 3 million shares available in Hong Kong and 27 million shares for international distribution, aiming for a price range of HKD 34.00 to 42.00 per share, with trading expected to commence on February 4, 2026 [2][3] Company Overview - Guoen Technology specializes in chemical new materials and gelatin, collagen, and related products, serving both the chemical and health industries [3] - The company operates in two main sectors: the large chemical sector, providing solutions to manufacturers in automotive, new energy, and home appliances, and the health sector, supplying raw materials for supplements and pharmaceuticals [3][4] Market Position - In the large chemical industry, Guoen is the second-largest company in China for organic polymer modified materials and organic polymer composite materials, holding a market share of 2.5% as of 2024 [4] - Guoen is also the largest producer of polystyrene in China by production capacity as of 2024 [4] Financial Performance - The company has shown strong revenue growth, with revenues of RMB 13.406 billion, RMB 17.439 billion, and RMB 19.188 billion for the fiscal years 2022, 2023, and 2024 respectively, reflecting a compound annual growth rate (CAGR) of 19.6% from 2022 to 2024 [7] - The sales figures for the fiscal years 2023 and 2024 indicate year-on-year growth rates of 30.1% and 10.0%, respectively [7] Market Trends - The market for organic polymer modified materials and organic polymer composite materials is projected to grow from RMB 303.8 billion in 2020 to RMB 544.8 billion by 2024, with a CAGR of 15.7% [8] - The market is expected to continue strong growth, reaching RMB 1,037.5 billion by 2029, with a forecasted CAGR of 14.1% from 2025 to 2029 [8] Use of Proceeds - The net proceeds from the share offering are estimated at approximately HKD 1.057 billion, with plans to allocate 50% for establishing a new production base in Thailand, 35% for expanding capacity in Yixing, and 10% for investments in Hong Kong [9]

Group 1 - The core viewpoint of the news is that Guoen Technology (国恩科技) is preparing for its IPO in the Hong Kong market, with a strong foundation and significant fundraising expectations [2][4] - Guoen Technology plans to globally issue approximately 30 million H-shares, with 3 million shares allocated for public offering in Hong Kong and 27 million shares for international offering [2] - The expected net fundraising amount is approximately HKD 1.058 billion, with funds allocated for expanding production capacity in Thailand and China, as well as for operational purposes [2][4] Group 2 - Guoen Technology specializes in new chemical materials and collagen products, serving the chemical and health industries, focusing on R&D, production, and sales [4] - The company ranks second in the organic polymer modification and composite materials industry in China by sales revenue, with a market share of 2.5%, and is the largest producer of polystyrene in China [4] - In the health sector, Guoen Technology's subsidiary, Dongbao Biological, has established a complete layout from collagen raw materials to end products, becoming a comprehensive group in the health segment [4] Group 3 - For the fiscal years 2022 to 2024, Guoen Technology's revenues were RMB 13.406 billion, RMB 17.439 billion, and RMB 19.188 billion, with corresponding profits of RMB 0.724 billion, RMB 0.540 billion, and RMB 0.721 billion [5] - The company has shown solid performance in its financial results, indicating a stable growth trajectory [5]

Core Viewpoint - The company, Guoen Technology (02768), is set to launch an IPO from January 27 to January 30, 2026, offering 30 million shares globally, with a price range of HKD 34.00 to HKD 42.00 per share, and aims to raise approximately HKD 1.058 billion for capacity expansion and operational purposes [1][5]. Group 1: Company Overview - Guoen Technology specializes in chemical new materials and gelatin, collagen, and related products, serving both the chemical and health industries [1]. - The company focuses on R&D, production, and sales of industrial and commercial products, catering to manufacturers in downstream sectors such as automotive, new energy, and home appliances [1]. Group 2: Chemical Industry Segment - In the chemical industry, the company has a comprehensive product range that includes upstream green petrochemical materials and midstream organic polymer modified materials [2]. - The company is the second-largest player in China's organic polymer modified materials and organic polymer composite materials market, with a market share of 2.5% as of 2024 [2]. - It is also the largest producer of polystyrene in China by capacity as of 2024 [2]. Group 3: Health Industry Segment - In the health sector, the company focuses on the natural collagen industry and has established a vertically integrated product line from collagen to end products [3]. - The company ranks second in China's bone gelatin production by output and is the leading domestic brand in this category as of 2024 [3]. - It is also the second-largest domestic brand in the hollow capsule production market by output as of 2024 [3]. Group 4: Investment and Fund Allocation - The company has secured cornerstone investment agreements totaling approximately HKD 320 million, with key investors including Liguang Investment and others [4]. - The net proceeds from the IPO are expected to be around HKD 1.058 billion, with allocations of 50% for expanding production capacity in Thailand, 35% for capacity expansion in China, 10% for investments in Hong Kong, and 5% for operational funds [5].

Core Viewpoint - The company, Guo'en Technology, is set to launch an IPO from January 27 to January 30, 2026, offering 30 million shares globally, with a price range of HKD 34.00 to HKD 42.00 per share, and aims to raise approximately HKD 1.058 billion for expansion and operational purposes [1][5]. Group 1: Company Overview - Guo'en Technology specializes in chemical new materials and gelatin, collagen, and related products, serving both the chemical and health industries [1]. - The company focuses on R&D, production, and sales of industrial and commercial products, catering to manufacturers in downstream sectors such as automotive, new energy, and home appliances [1]. Group 2: Chemical Industry Segment - In the chemical industry, the company has a comprehensive product range that includes upstream green petrochemical materials and midstream organic polymer modified materials [2]. - The company is the second-largest player in China's organic polymer modified materials and organic polymer composite materials market, with a market share of 2.5% as of 2024 [2]. - It is also the largest producer of polystyrene in China by production capacity as of 2024 [2]. Group 3: Health Industry Segment - In the health sector, the company focuses on the natural collagen industry, with a vertical integration strategy that spans from collagen to end products [3]. - The company is the second-largest producer of bone gelatin in China by output and the largest domestic brand in this category as of 2024 [3]. - It ranks as the second-largest domestic brand in the hollow capsule production sector in China by output as of 2024 [3]. Group 4: Investment and Fund Allocation - The company has secured cornerstone investment agreements totaling approximately HKD 320 million, with investors including several financial institutions [4]. - The net proceeds from the IPO are expected to be around HKD 1.058 billion, with allocations planned for expanding production capacity in Thailand (50%), China (35%), and investments in Hong Kong (10%) [5].

Group 1 - The company, Guoen Technology (02768.HK), plans to globally offer 30 million H-shares, with 3 million shares available in Hong Kong and 27 million shares for international distribution, with the offering period from January 27 to January 30, 2026, and expected pricing on February 2, 2026 [1] - The expected share price range is between HKD 34.00 and HKD 42.00, with a trading unit of 200 shares, and the shares are anticipated to start trading on the Hong Kong Stock Exchange on February 4, 2026 [1] - Guoen Technology specializes in chemical new materials and gelatin, collagen, and related products, serving the chemical and health industries, focusing on R&D, production, and sales [1] Group 2 - The company has entered into cornerstone investment agreements, with cornerstone investors agreeing to subscribe for shares totaling approximately HKD 320 million, assuming a maximum share price of HKD 42.00 [2] - The cornerstone investors include several entities such as Liguan Investment Limited, SLD International Enterprises Limited, and others [2] Group 3 - Assuming a mid-range share price of HKD 38.00, the company estimates net proceeds from the global offering to be approximately HKD 1.0577 billion [3] - The company plans to allocate about 50% or HKD 528.5 million to establish a new production base in Thailand to expand capacity, 35% or HKD 370.5 million to enhance capacity at its Yixing production base, and 10% or HKD 105.7 million for investments in Hong Kong [3] - The remaining 5% or approximately HKD 53 million is expected to be used for working capital and general corporate purposes [3]

格隆汇1月27日丨国恩科技(02768.HK)发布公告，公司拟全球发售3000万股H股，中国香港发售股份300 万股，国际发售股份2700万股(以上可予重新分配)；2026年1月27日至1月30日招股，预期定价日为2月2 日；发售价每股发售股份34.00-42.00港元，H股的每手买卖单位将为200股，招商证券国际为独家保荐 人；预期H股将于2026年2月4日开始于联交所买卖。 ...

青島國恩科技股份有限公司 QINGDAO GON TECHNOLOGY CO., LTD. （於中華人民共和國註冊成立的股份有限公司） 股份代號 : 2768 全球發售 獨家保薦人、保薦人兼整體協調人、聯席整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 聯席整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 聯席賬簿管理人及聯席牽頭經辦人 重要提示 閣下如對本文件任何內容有任何疑問，應諮詢獨立專業意見。 QINGDAO GON TECHNOLOGY CO., LTD. 青島國恩科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 全球發售 全球發售的發售股份數目 ： 30,000,000股H股 香港發售股份數目 ： 3,000,000股H股（可予重新分配） 國際發售股份數目 ： 27,000,000股H股（可予重新分配） 最高發售價 ： 每股H股42.00港元，另加1%經紀佣 金、0.0027%證監會交易徵費、 0.00565%聯交所交易費及0.00015% 會財局交易徵費（須於申請時以港元繳 足，多繳股款可予退還） 面值 ： 每股H股人民幣1.00元 股份代號 ： 2768 聯席 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示 概不就因本公告全部或任何部分內容而產生或因依賴該等內容引致的任何損失承擔任何責任。 除本公告另有界定者外，本公告所用詞彙與青島國恩科技股份有限公司（「本公司」）所刊發日期 為2026年1月27日的招股章程（「招股章程」）所界定者具有相同涵義。 本公告僅供參考，並不構成對進行收購、購買或認購任何證券的邀請或要約。本公告並非招股 章程。有意投資者須先細閱招股章程瞭解有關下文所述全球發售的詳細資料，方決定是否投資 於發售股份。任何有關發售股份的投資決定應僅依賴招股章程所載的資料作出。 本公告不得直接或間接於或向美國（包括其領土及屬地、美國任何州以及哥倫比亞特區）發佈、 刊發或派發。本公告並不構成或組成於美國或任何其他司法管轄區購買或認購證券的任何要 約或招攬的一部分。發售股份不曾亦不會根據《1933年美國證券法》（經不時修訂）（「美國證券 法」）或美國任何州或其他司法管轄區的證券法登記。發售股份不得在美國境內提呈發售、出 售、抵押或以其他方式轉 ...

香港聯合交易所有限公司 (香港交易及結算所有限公司全資附屬公司) THE STOCK EXCHANGE OF HONG KONG LIMITED (A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited) 紀律行動聲明 聯交所對佳源國際控股有限公司（已除牌，前股份代號：2768）一名前 董事的紀律行動 制裁 香港聯合交易所有限公司（聯交所） 向佳源國際控股有限公司（該公司）前非執行董事沈天晴先生（下稱董事）作出董事不適 合性聲明及譴責。 董事不適合性聲明是指聯交所認為，上列董事不適合擔任該公司或其任何附屬公司的董事 或高級管理階層成員。 實況概要 根據《上市規則》第 3.09C 及 3.20 條，每名董事有責任 (i) 在上巿科及／或上巿委員會所 進行的任何調查中給予合作；(ii) 及時及坦白地答覆向其提出的任何問題；及 (iii) 在其不再 出任董事的日期起計三年內向聯交所提供其最新的聯絡資料，否則聯交所發送至其紀錄中 董事的最後所知地址的任何文件／通知書均視作已向董事本人送達。 上市科為調查（其中包括）上列董事是否已履行《 ...

Group 1 - The announcement details the release and pledge of shares by the controlling shareholder, Mr. Wang Aiguo, of Qingdao Guoen Technology Co., Ltd. [1] - The company confirms that the information disclosed is true, accurate, and complete, with no misleading statements or significant omissions [1] - Mr. Wang Aiguo's credit status is good, and he has the financial capability to repay, indicating that the pledged shares do not pose a risk of forced liquidation [3] Group 2 - As of the announcement date, the total number of pledged shares held by the shareholder and their concerted parties is outlined [2][3] - The company states that the share pledge will not adversely affect its operations or governance, and there are no obligations for performance compensation [3] - Relevant documents, including proof of share release and pledge, are available for review [4]